Arstasis Information

View Top Employees from Arstasis

Self-Sealing Access, Implant Free… Naturally. AXERA® Access seals securely using nothing but the femoral artery wall itself. AXERA® Access creates a long, shallow angle arteriotomy that delivers significant tissue-on-tissue overlap through the femoral artery wall. This creates a self-sealing opening that requires only minimal compression for rapid hemostasis and secure closure. Self-sealing access also provides excellent patient comfort and quick ambulation. And because AXERA® Access deposits no foreign material, it eliminates all implant related complications. Self-Sealing Access Benefits Demonstrated in RECITAL Study* - Significant decrease in manual compression time by half or more - Elevate bed to 45º within 15-30 minutes of hemostasis - Ambulate patients in 1 to 2 hours - No patient implant delivers excellent patient comfort and safety *AXERA 2 IFU, SECURE II and RECITAL clinical study summaries.

Website	http://www.arstasis.com
Revenue	$51.5 million
Funding	$102.3 million
Employees	23 (1 on RocketReach)
Founded	2004
Address	6500 Kaiser Dr Ste 120, Fremont, California 94555, US
Phone	+1 877-717-8001
Technologies	JavaScript , HTML , Nginx +5 more (view full list)
Industry	Manufacturing, Medical Device, Manufacturing General, Health Care, Cardiovascular, Peripheral Vascular, Interventional Radiology
Web Rank	34 Million
Keywords	Medical Technology, Healthcare Technology, Biomedical Engineering, Hemostasis, Minimally Invasive, Endovascular, Thrombosis Prevention, Bleeding Control, Wound Closure, Vascular Surgery, Interventional Cardiology, Peripheral Vascular Disease
Competitors	Tempus Labs, Inc., Guardant Health, GRAIL, Myriad Genetics, Foundation Medicine, Caris Life Sciences, NantHealth, PathAI, Black Diamond Therapeutics, Sequencing +38 more (view full list)
SIC	SIC Code 38 Companies, SIC Code 384 Companies
NAICS	NAICS Code 33 Companies, NAICS Code 339 Companies